17,768 Shares in Halozyme Therapeutics, Inc. $HALO Purchased by Cardinal Capital Management

Cardinal Capital Management acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 3rd quarter, HoldingsChannel.com reports. The fund acquired 17,768 shares of the biopharmaceutical company’s stock, valued at approximately $1,303,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Newbridge Financial Services Group Inc. bought a new stake in shares of Halozyme Therapeutics in the second quarter valued at approximately $32,000. Employees Retirement System of Texas purchased a new position in Halozyme Therapeutics in the 2nd quarter valued at approximately $34,000. Asset Management One Co. Ltd. bought a new stake in Halozyme Therapeutics during the 2nd quarter valued at $98,000. Global Retirement Partners LLC lifted its position in shares of Halozyme Therapeutics by 21.6% during the third quarter. Global Retirement Partners LLC now owns 1,413 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 251 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 174 shares during the period. Institutional investors own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on HALO shares. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, December 29th. The Goldman Sachs Group reiterated a “sell” rating and set a $56.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Wall Street Zen downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 6th. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Tuesday, November 4th. Finally, Benchmark increased their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Eight equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $76.45.

Insider Buying and Selling

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $69.13, for a total value of $1,382,600.00. Following the transaction, the chief executive officer owned 733,719 shares of the company’s stock, valued at $50,721,994.47. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the sale, the director directly owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. This trade represents a 4.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 45,661 shares of company stock worth $3,139,257. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Down 4.0%

HALO stock opened at $72.13 on Friday. The company’s 50 day moving average is $68.13 and its 200 day moving average is $66.46. The stock has a market cap of $8.48 billion, a price-to-earnings ratio of 15.19, a price-to-earnings-growth ratio of 0.33 and a beta of 0.94. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59. Halozyme Therapeutics, Inc. has a 1-year low of $47.50 and a 1-year high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. The business had revenue of $354.26 million during the quarter, compared to analysts’ expectations of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The business’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.27 EPS. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.